JNJ · News · 20261107N

Icotyde Psoriatic Arthritis Progress

JOHNSON & JOHNSON · 2026-11-07 · Importance 30 · Surprise 42

Johnson & Johnson reported positive Phase 3 results for ICOTYDE (icotrokinra) in biologic-naive adults with active psoriatic arthritis. At Week 16, 58% of treated patients achieved an ACR20 response versus 41% on placebo, and 29% achieved ACR50. ICOTYDE is a once-daily oral peptide that targets the IL-23 receptor; results also showed joint and skin improvements with no new safety signals.

Key facts

• Johnson & Johnson reported positive Phase 3 results for icotrokinra in biologic-naive adults with active psoriatic arthritis. source
• At Week 16, 58% of ICOTYDE-treated patients achieved an ACR20 response, compared with 41% of patients receiving placebo. source
• At Week 16, 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response. source
• Johnson & Johnson reported no new safety signals for icotrokinra in the Phase 3 psoriatic arthritis study. source
• ICOTYDE is described as the first and only targeted oral peptide that precisely blocks the IL-23 receptor. source
• ICOTYDE is a once-daily pill. source